Another Unprecedented OS Win in Extensive-Stage SCLC With Tarlatamab Maintenance

(MedPage Today) -- Overall survival (OS) in extensive-stage small-cell lung cancer (ES-SCLC) approached 2 years with tarlatamab (Imdelltra) combination maintenance therapy after first-line chemoimmunotherapy, a large randomized trial showed. Median...